Mattson Financial Services LLC Buys New Shares in Insulet Corporation $PODD

Mattson Financial Services LLC bought a new stake in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 5,689 shares of the medical instruments supplier’s stock, valued at approximately $1,787,000.

Several other hedge funds have also recently added to or reduced their stakes in PODD. Farther Finance Advisors LLC raised its position in Insulet by 85.1% in the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier’s stock worth $236,000 after purchasing an additional 412 shares in the last quarter. GAMMA Investing LLC raised its position in Insulet by 4.3% in the first quarter. GAMMA Investing LLC now owns 2,529 shares of the medical instruments supplier’s stock worth $664,000 after purchasing an additional 105 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Insulet by 13.9% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,028 shares of the medical instruments supplier’s stock worth $795,000 after purchasing an additional 370 shares in the last quarter. Exchange Traded Concepts LLC raised its position in Insulet by 225.4% in the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier’s stock worth $408,000 after purchasing an additional 1,075 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its position in Insulet by 2.9% in the first quarter. Janney Montgomery Scott LLC now owns 5,405 shares of the medical instruments supplier’s stock worth $1,419,000 after purchasing an additional 154 shares in the last quarter.

Insulet Stock Performance

NASDAQ PODD opened at $316.29 on Friday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm has a market cap of $22.26 billion, a price-to-earnings ratio of 96.14, a PEG ratio of 2.61 and a beta of 1.40. The company has a 50 day moving average of $325.99 and a 200-day moving average of $301.60. Insulet Corporation has a 1-year low of $226.50 and a 1-year high of $353.50.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Zacks Research raised shares of Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. The Goldman Sachs Group dropped their price target on shares of Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Rothschild & Co Redburn increased their price target on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Wells Fargo & Company increased their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Finally, Canaccord Genuity Group raised their price objective on shares of Insulet from $353.00 to $399.00 and gave the stock a “buy” rating in a report on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $348.05.

Insider Buying and Selling

In related news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.